WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (NYSE: RBOT, RBOT.WS), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, announced today that it has entered into a securities purchase agreement with a single institutional investor to purchase the Company's Class A common stock and pre-funded warrants in a registered direct offering and warrants to purchase its Class A common stock in a concurrent private placement. The combined effe. ...

The company dominates the high-growth market of surgical robots.Intuitive Surgical (ISRG 2.11%) stock has proven itself to be a winner for investors over time, advancing more than 700% over the past decade. This is thanks to the company's leadership in the high-growth market of robotic surgery and its ability to maintain that position and keep earnings roaring higher.Intuitive's flagship product is the Da Vinci surgical robot, and in the latest quarter, the company reached an install base of more than 10,40 ...

Market Overview - The global surgical robotics market was valued at approximately $4.31 billion in 2024 and is projected to reach $9.6 billion by 2033, at a CAGR of 9.3% [2] - North America holds about 39.6% of the worldwide market share in 2025 [2] Company Insights: Intuitive Surgical (ISRG) - Intuitive Surgical maintains nearly 60% of the global market share, supported by a strong recurring revenue stream from its installed base [3] - The da Vinci Surgical System has evolved through five generations, integrating AI and advanced technologies, enhancing surgical precision and expanding its applicability [4] - The latest model, da Vinci 5, has seen 180 placements by mid-2025, with nearly 700 systems installed globally [5] - Recurring revenues from instruments and digital services account for 85% of total revenues, with per-procedure spend remaining steady at nearly $1,800 [6] - The Ion endoluminal platform is emerging as a growth driver, with over 900 systems installed and a 50% year-over-year increase in procedures [7] - Intuitive Surgical has raised its 2025 growth outlook to 15.5-17% due to rising adoption of da Vinci 5 and Ion's penetration [8] Company Insights: Zimmer Biomet (ZBH) - Zimmer Biomet is focusing on its expanding knee portfolio and innovation strategy to strengthen its position in the musculoskeletal market [9] - The company's ROSA Robotic Platform and cementless knees are driving steady growth, with a 150 basis point improvement in sequential growth in 2025 [10] - The Persona Revision Knee has surpassed 100 accounts in Europe, with expectations for accelerated momentum [11] - Zimmer Biomet's strategic plan includes investing in leadership, operational excellence, and innovation, supported by acquisitions [12] - The company has shown steady gains with 1.8% growth in knees, 4.0% in hips, and 4.9% in S.E.T during the second quarter [13] Price Performance and Valuation - Shares of Intuitive Surgical have declined 15.5% year-to-date, while Zimmer Biomet's stock is down 12.9% [14] - Intuitive Surgical's valuation has declined but still trades above the industry average, while Zimmer Biomet trades at a significant discount [18] - Zimmer Biomet currently carries a Zacks Rank 2 (Buy), while Intuitive Surgical has a Zacks Rank 4 (Sell), indicating a better investment opportunity in Zimmer Biomet [24] Conclusion - Both companies are positioned to benefit from the rising demand for robotic surgery, particularly in the U.S. market [23] - Zimmer Biomet offers a more attractive valuation compared to Intuitive Surgical, which is trading above its industry's valuation [23]

I thought I was going to surprise you by introducing myself by the looks of it at least. I am a gynecological robotic and a cancer surgeon. But there's little more.If you look deeper, there is an engineer at heart. And I thought I left that engineer behind until 15 years ago, he returned. A few years into my practice, a 17-year-old girl came to me with a complex genetic problem of an undeveloped uterus with the trapped menstrual blood.The medical indication was not clear. remove the uterus that was indicate ...

Key Takeaways ISRG's SP procedures in Korea rose 112% with strong adoption across specialties.Europe sees steady growth of ISRG's SP with new clearances lowering costs and broadening use.SP utilization grew 30%, showing higher throughput per installed ISRG system.Intuitive Surgical’s (ISRG) second-quarter earnings underscored the accelerating momentum of its single-port (SP) platform, with international adoption emerging as a notable growth driver. Korea continues to lead, posting a 112% year-over-year incr ...

Key Points Intuitive Surgical's stock has enriched its many investors. Its future looks promising, too. The shares trade at lower-than-average levels, presenting a compelling opportunity for long-term investors. 10 stocks we like better than Intuitive Surgical › If you don't know much about Intuitive Surgical (NASDAQ: ISRG), you might want to remedy that. It's a very impressive growth stock. Its past performance is likely to wow you, and its future looks very promising. Over the past decade, Int ...

Financial Data and Key Metrics Changes - Total operating expenses for Q2 2025 were $13.5 million, a 24% decrease from $17.7 million in Q2 2024 [14] - GAAP net loss for Q2 2025 was $13.2 million or $2.23 per share, compared to a net loss of $15.2 million or $2.59 per share in Q2 2024 [15] - Non-GAAP adjusted net loss for Q2 2025 was $13.3 million or $2.23 per share, compared to $16.8 million or $2.86 per share in Q2 2024 [15] - Cash burn rate for Q2 2025 was approximately $13.4 million, with an expectation of full-year 2025 cash burn around $50 million [16] Business Line Data and Key Metrics Changes - Research and development expenses for Q2 2025 were $9.1 million, down from $10.9 million in Q2 2024 [14] - General and administrative expenses for Q2 2025 were $4.1 million, compared to $5.6 million in Q2 2024 [14] - Sales and marketing expenses for Q2 2025 were $300,000, down from $1.2 million in Q2 2024 [14] Company Strategy and Development Direction - The company is focusing on completing a fully integrated production equivalent system before initiating clinical trials, shifting away from near-term targets for first clinical use (FCU) [11] - The new CEO emphasizes the importance of ensuring the system is ready for commercialization before proceeding with clinical trials [10][11] - The company aims to refine its timelines and evaluate progress across development programs while engaging with the Board and investors regarding capital strategy [12] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the challenges of the current market environment but expresses confidence in the company's technology and mission to transform surgical care [18] - The new CEO is optimistic about the company's potential and the need for a system that addresses real problems in the surgical field [40][44] - Management is committed to providing reliable guidance to investors once a clearer understanding of development timelines is established [36][58] Other Important Information - The company ended Q2 2025 with approximately $24 million in cash, cash equivalents, and short-term investments [15] - The leadership transition is seen as an opportunity to reassess the company's development path and strategy [5][6] Q&A Session Summary Question: Can you discuss the process of prioritizing system readiness and the impact on clinical trial timelines? - The new CEO is focused on understanding the requirements for a full production equivalent system and ensuring that resources are allocated effectively to avoid rushing into clinical trials with an incomplete system [24][25] Question: What was anticipated to be spent on clinical trials, and how does that affect cash burn guidance? - Current budgeted costs for clinical trials are not expected to materially change the overall 2025 budget, as most groundwork does not require significant spending [30] Question: What milestones should investors expect by the end of the year? - The CEO indicates that it is too early to provide specific dates for milestones, as clarity will come after a thorough assessment of the current development status [35][36] Question: How does the company view its ability to fund development with current cash on hand? - The CEO expresses confidence in the company's potential and the need for the system being developed, emphasizing that the groundwork has already been laid for future success [39][41] Question: What led to the conclusion that the system is not ready for first in human trials? - Management identified several issues that need to be addressed before proceeding, including hardware and software adjustments, which require additional time and effort [50][52] Question: Will the timeline for clinical milestones shift significantly? - The CEO cannot provide specific guidance on timeline shifts until the assessment is completed, but he is optimistic about the visibility of the goal line as the assessment progresses [58][59]

Core Insights - The company reported total revenue of $2.44 billion in Q2 2025, a 21% year-over-year increase, driven by strong growth in systems revenue and procedure volumes [5][39][46] - Pro forma gross margin decreased to 67.9% from 70% in Q2 2024, attributed to higher facility costs and a greater mix of lower-margin products [7][42] - Da Vinci procedures grew by 17%, with notable increases in ION and SP procedures, which grew by 52% and 88% respectively [5][26][31] Financial Performance - Pro forma operating margin reached 39%, and pro forma earnings per share rose 23% to $2.19 [7][46] - The installed base of da Vinci systems increased by 14% to nearly 10,500, with 395 systems placed in Q2 2025, marking a 16% increase from the previous year [6][31][36] - Cash and investments at quarter-end totaled $9.5 billion, up from $9.1 billion in the prior quarter [10][47] Market Dynamics - The company acknowledged ongoing financial pressures in international markets, particularly in Japan, China, and Europe, affecting capital performance [3][37] - Tariff impacts for 2025 are estimated to be around 100 basis points, with potential for significant incremental effects on cost of sales [4][43] - Uncertainty regarding Medicaid coverage in the US could create financial challenges for hospitals, potentially affecting capital budgets [4][32] Product Developments - The da Vinci five platform is in broad launch in the US and has received regional clearances in Europe and Japan, with early adopter interest noted [11][19] - New product clearances include the Vessel Sealer Curved and a procedure clearance for tracheobronchoplasty [9][23] - Digital initiatives, including force feedback and case insights features, are expected to enhance surgical outcomes and efficiency [10][54] Guidance and Outlook - The company revised its 2025 da Vinci procedure growth outlook to 15.5%-17% and raised the pro forma gross margin projection to 66%-67% [8][55] - Operating expense growth guidance remains at 10%-14% for 2025, reflecting investments in new facilities and R&D [8][57] - Capital expenditures are estimated to be between $650 million and $725 million, primarily for facility construction [8][58]

Core Insights - SS Innovations International, Inc. has successfully completed the world's first intercontinental robotic cardiac telesurgery, showcasing the capabilities of its SSi Mantra 3 surgical robotic system [1][4][6] Company Overview - SS Innovations is dedicated to making robotic surgery affordable and accessible globally, with a focus on innovative surgical robotic technologies [1][8] - The company has received regulatory approval from India's Central Drugs Standard Control Organization for both teleproctoring and telesurgery, distinguishing it from other surgical robotic companies [7] Surgical Achievements - The recent cardiac procedure involved a robotic atrial septal defect closure performed remotely from Strasbourg, France to Indore, India, covering a distance of over 4,000 miles [2][3] - To date, SS Innovations has completed 35 telesurgeries, including 10 cardiac procedures, demonstrating the effectiveness of the SSi Mantra system in complex surgeries [6] Technological Features - The SSi Mantra surgical robotic system includes advanced features such as modular robotic arms, a 3D 4K monitor, and the ability to superimpose 3D diagnostic imaging models, enhancing surgical precision and safety [12]

Revenue & Growth Trends Key Takeaways As robotic-assisted surgery continues its rising adoption in modern medicine, two industry leaders — Intuitive Surgical (ISRG) and Stryker (SYK) — are shaping the future of robotic-assisted surgery. Intuitive, renowned for its da Vinci Surgical System, continues to dominate the soft tissue surgery space. In contrast, Stryker has established a firm foothold in orthopedic procedures through its Mako robotic platform. Both companies are aggressively pursuing innovation and ...